Skip to main content
Log in

Neonatal diabetes mellitus due to L233F mutation in the KCNJ11 gene

  • Case Report
  • Published:
World Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Background

Neonatal diabetes mellitus (NDM) due to KCNJ11 gene mutation presents with diabetes in the first 3 months of life and sometimes with neurological features like developmental delay, muscle weakness and epilepsy.

Methods

A 5-week-old boy presented with diabetic ketoacidosis. Molecular genetic analysis of the patient revealed heterozygous missense mutation, L233F in the KCNJ11 gene, while his mother was mosaic for the same mutation.

Results

The treatment strategy was changed from insulin injections to oral glibenclamide and with a better glycemic control.

Conclusion

The patient with NDM due to mutation L233F (not reported till date) in the KCNJ11 gene can be successfully treated with oral glibenclamide therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838–1849.

    Article  PubMed  CAS  Google Scholar 

  2. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54:2503–2513.

    Article  PubMed  CAS  Google Scholar 

  3. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A 2004;101:17539–17544.

    Article  PubMed  CAS  Google Scholar 

  4. Flanagan SE, Clauin S, Bellanné-Chantelot C, de Lonlay P, Harries LW, Gloyn AL, et al. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 2009;30:170–180.

    Article  PubMed  CAS  Google Scholar 

  5. Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467–477.

    Article  PubMed  CAS  Google Scholar 

  6. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004;89:5504–5507.

    Article  PubMed  CAS  Google Scholar 

  7. Zlotogora J. Germ line mosaicism. Hum Genet 1998;102:381–386.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rajesh Joshi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Joshi, R., Phatarpekar, A. Neonatal diabetes mellitus due to L233F mutation in the KCNJ11 gene. World J Pediatr 7, 371–372 (2011). https://doi.org/10.1007/s12519-011-0254-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12519-011-0254-z

Key words

Navigation